Who are Placebo for Rosuvastatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crestor, Lipitor, FLUVASTATIN SODIUM, Lescol, Atorvastatin-omeprazole, Rosuvastatin-pantoprazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-for-rosuvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo for Rosuvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo for Rosuvastatin (Placebo for Rosuvastatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: statin. Area: Cardiovascular.

phase 3 statin HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Placebo for Rosuvastatin (Placebo for Rosuvastatin) — Merck Sharp & Dohme LLC. Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo for Rosuvastatin TARGET	Placebo for Rosuvastatin	Merck Sharp & Dohme LLC	phase 3	statin	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
Atorvastatin-omeprazole	Atorvastatin-omeprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Fixed-dose combination (statin + proton pump inhibitor)	HMG-CoA reductase (atorvastatin); H+/K+-ATPase (omeprazole)
Rosuvastatin-pantoprazole	Rosuvastatin-pantoprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Statin + proton pump inhibitor combination	HMG-CoA reductase (rosuvastatin); H+/K+-ATPase (pantoprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (statin class)

FutureChem · 1 drug in this class
HTA Co., Ltd. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
VA Office of Research and Development · 1 drug in this class
Zhejiang Hisun Pharmaceutical Co. Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo for Rosuvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-rosuvastatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab